fbpx

Grey Wolf Therapeutics completes £2.5 million Series A2 financing to accelerate development of therapies targeting ERAP2

Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for...

The most discussed and shared scientific research of 2019

Climate crisis, artificial intelligence, and vaccines top the list of 2019’s most discussed research From the increasing use of artificial intelligence to the climate emergency facing us all, many of this year’s most polarizing issues feature in the Altmetric Top 100,...